These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 31685745)

  • 1. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
    Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
    Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet.
    Dorcely B; Nitis J; Schwartzbard A; Newman JD; Goldberg IJ; Sum M
    Curr Diabetes Rev; 2021; 17(2):243-246. PubMed ID: 32178617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
    Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
    Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
    Dull RB; Spangler ML; Knezevich EL; Lau BM
    J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
    Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
    BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delayed euDKA Associated With Dapagliflozin After Pancreatitis.
    Wu G; Wu S; Tang J; Wu H
    Clin Ther; 2023 Jul; 45(7):e167-e170. PubMed ID: 37248092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
    Ozer O; Yorulmaz G
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):110-111. PubMed ID: 33115581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
    Paul N; Jonklaas J
    Diabetes Metab Syndr; 2021; 15(1):361-363. PubMed ID: 33517150
    [No Abstract]   [Full Text] [Related]  

  • 9. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
    Mistry S; Eschler DC
    AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
    Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
    Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
    Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
    J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
    Valek R; Von der Mark J
    Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
    Allison R; Goldstein D; Musso MW
    J Emerg Med; 2019 Jul; 57(1):e1-e3. PubMed ID: 31027990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis.
    Wan Azman SS; Sukor N; Abu Shamsi MY; Ismail I; Kamaruddin NA
    Front Endocrinol (Lausanne); 2022; 13():867647. PubMed ID: 35712244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
    Leader R; Cowen J; Rajeev SP
    BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ketogenic diet as a trigger for diabetic euglycaemic ketoacidosis in a patient under treatment with iSGLT2].
    Nubiola A; Ternianov A; Remolins I
    Hipertens Riesgo Vasc; 2020; 37(1):39-41. PubMed ID: 31734176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
    Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
    J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.
    Kuchay MS; Mishra SK; Mehta Y
    Diabetes Metab Syndr; 2021; 15(3):909-911. PubMed ID: 33915345
    [No Abstract]   [Full Text] [Related]  

  • 19. Empagliflozin-Associated Euglycemic Diabetic Ketoacidosis Masked by Urinary Tract Infection.
    Chauhan S; Diaz V; Ogbu IR; Sanchez JRP; Manov AE; Shah P
    Cureus; 2024 Aug; 16(8):e66408. PubMed ID: 39246944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
    Soni P; Kumar V; Saradna A; Kupfer Y
    Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.